

## Correction: *Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer*

Wang H, Ma H, Sové RJ, *et al.* Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer. *J Immunother Cancer* 2021;9:e002100. doi: 10.1136/jitc-2020-002100

This article has been corrected since it first published. The provenance and peer review statement has been added.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

*J Immunother Cancer* 2021;9:e002100corr1. doi:10.1136/jitc-2020-002100corr1

